Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
|
|
- Anastasia York
- 6 years ago
- Views:
Transcription
1 Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin MD
2 Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC The following presentation represents the views of the speaker at the time of the presentation. This information is meant for educational purposes, and should not replace other sources of information or your medical judgment. Andre Roussin MD, FRCP, CSPQ; September 2016 A. Roussin MD
3 Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Conflict Disclosures Advisor or advisory boards: Bayer, BI, BMS, Leo, Merck, Pfizer, Sanofi Research funding: Astra-Zeneca and Bayer Speaker: Bayer, BI, BMS, Leo, Merck, Pfizer and Sanofi Andre Roussin MD, FRCP, CSPQ; September 2016 A. Roussin MD
4 DEBATE: DOAC vs Good Old Warfarin Objectives Recognize the benefits and harms associated with DOACs for the prevention and treatment of thromboembolic events Recognize the benefits and harms associated with warfarin for the prevention and treatment of thromboembolic events Compare and contrast the benefits and harms of DOACs versus warfarin in complex patients with multiple comorbidities A. Roussin MD
5 DOAC vs VKA (warfarin) Pharmacological aspects Warfarin DOAC Onset of action Slow (5 days) and unpredictable Rapid (2 hours) and predictable Dosing Variable and difficult Fixed, according to creatinine Food interactions Numerous None (except rivaroxaban: meal) Drug interactions Very long list Few CKD No impact Impact if severe (Clear < 25-30) Liver disease Impact on warfarin and coagulation factors Contra-indicated Child-Pugh B + C A. Roussin MD
6 DOAC vs VKA (warfarin) "Strategic" aspects Warfarin DOAC Routine monitoring Necessary Useless AC effect duration Bleeding Surgery Antidote 2 to 5 days 1 day to activity to 25% PCC (Beriplex or Octaplex ) with Vit K Idarucizumab for Dabi. Andexanet for Api. / Rivaro. PCC (Beriplex or Octaplex )? Daily cost of medication $0.45 average $2.80 (riva) to $3.20 (dabi and api) Strategic costs Rx cost + INR/visits + costs of Stroke (AF), bleeding (AF + VTE) and days of supplemetary hospitalization (AF + VTE) Rx cost + QALY A. Roussin MD
7 DOAC vs Warfarin for AF Stroke or Systemic embolism Relative risk (IC 95 %) RE-LY [Dabigatran 150 mg] 0,66 (0,53-0,82) ROCKET AF [Rivaroxaban] 0,88 (0,75-1,03) ARISTOTLE [Apixaban] 0,80 (0,67-0,95) ENGAGE AF-TIMI 48 [Edoxaban 60 mg] 0,88 (0,75-1,02) All 0,81 (0,73-0,91) p = < 0,0001 N = ,5 DOAC better 1 VKA better 2 Heterogeneity p = 0,13 Ruff CT et all. Lancet. A. Roussin MD
8 DOAC vs Warfarin for AF Major bleeding Study DOAC Relative risk (IC 95 %) ROCKET-AF RE-LY Rivaroxaban à 20 mg qd Dabigatran à 150 mg bid Dabigatran à 110 mg bid ENGAGE ARISTOTLE Édoxaban à 60 mg qd Édoxaban à 30 mg qd Apixaban* à 5 mg bid 0,1 DOAC better 1 VKA better 2 Connolly SJ et coll., RE-LY. N Engl J Med. 2009;361: ; Connolly SJ et coll., poure-ly. N Engl J Med. 2011;363(19): (mise à jour); Patel MR et coll. ROCKET AF. N Engl J Med. 2011;365: ; Granger CB et coll., ARISTOTLE. N Engl J Med. 2011; 365: Giugliano RP et coll., ENGAGE AF-TIMI 48. N Engl J Med. 19 nov A. Roussin MD
9 DOAC vs Warfarin for AF Intracranial bleeding All DOACs reduce the rate of intracranial blededing compared to warfarin. Study DOAC Relative risk (IC 95 %) ROCKET-AF RE-LY ENGAGE ARISTOTLE Rivaroxaban 20 mg qd Dabigatran 150 mg bid Dabigatran 110 mg bid Édoxaban 60 mg qd Édoxaban 30 mg qd Apixaban 5 mg bid 0,1 DOAC better 1 2 VKA better Connolly SJ et coll., RE-LY. N Engl J Med. 2009;361: ; Connolly SJ et coll., poure-ly. N Engl J Med. 2011;363(19): (mise à jour); Patel MR et coll. ROCKET AF. N Engl J Med. 2011;365: ; Granger CB et coll., ARISTOTLE. N Engl J Med. 2011; 365: Giugliano RP et coll., ENGAGE AF-TIMI 48. N Engl J Med. 19 nov A. Roussin MD
10 DOAC vs Warfarin: GI bleeding (for AF) DOACs are associated with similar or higher risk of GI bleeding than warfarin (AF patients) DOAC No. of éven. (% an) Warfarin HR Dabigatran 110 Dabigatran (1.15) 126 (1.07) (1.56) 126 (1.07) 1.48 Rivaroxaban* Apixaban 224 (3.15) 154 (2.16) 105 (0.76) 119 (0.86) DOAC better VKA better *Rivaroxaban: *% and not %/yr are reported; RR, not reported, was calculated: Connolly SJ, et al. N Engl J Med 2010; 363(19): , suppl app. Patel MR, et al. N Engl J Med. 2011; 365: Granger CB, et al. N Engl J Med. 2011; 365: A. Roussin MD
11 DOAC vs Warfarin for AF Total mortality DOACs reduced the rate of total mortality compared to warfarin. Study DOAC Relative risk(ic 95 %) ROCKET-AF Rivaroxaban 20 mg qd RE-LY Dabigatran 150 mg bid Dabigatran 110 mg bid ENGAGE ARISTOTLE Édoxaban 60 mg qd Édoxaban 30 mg qd Apixaban 5 mg bid 0,1 DOAC better 1 2 VKA better Connolly SJ et coll., RE-LY. N Engl J Med. 2009;361: ; Connolly SJ et coll., poure-ly. N Engl J Med. 2011;363(19): ; Patel MR et coll. ROCKET AF. N Engl J Med. 2011;365: ; Granger CB et coll., ARISTOTLE. N Engl J Med. 2011; 365: Giugliano RP et coll., ENGAGE AF-TIMI 48. N Engl J Med. 19 nov A. Roussin MD
12 Peri-procedural bleeding Dabigatran vs Warfarin 4591 patients had an invasive procedure during RELY Healey et al. Circulation 2012; 126: A. Roussin
13 DOACs for VTE Phase III studies UHF or LMWH As effective with less bleeding than VKA Front line Fontana P et al. EHJ 2014 A. Roussin MD
14 VTE treatment options: AT 10 Warfarin, UFH, LMWH and DOACs Warfarin LMWH Rather than VKA 2B or DOAC 2C DOAC Rather than VKA 2B LMWH sc or UHF iv or sc. or fondaparinux sc Warfarin INR 2 3 rather than LMWH 2C Transition treatment offering immediate AC CANCER, (6 months ) LMWH monotherapy Rivaroxaban 15 mg BID for 21 days, then 20 mg DOD LMWH (UHF) for 5-10 days, then dabigatran 150/110 mg BID Apixaban 10 mg BID for 7 days, then 5 mg BID 6 months then 2.5 mg BID Special cases- UFH UHF if CrCl < 30 ml/min, increased bleeding risk, need for rapid reversal or if thrombolysis contemplated A. Roussin MD
15 DOACS and VTE for acute phase Non head-to-head comparisons APIXABAN 1 RIVAROXABAN 2,3 DABIGATRAN 4,5 Trial design: double-blind Yes No Yes Use of LMWH and/or UFH lead-in No No Yes Duration of treatment 6 months 3, 6, or 12 months 6 months Non-inferior efficacy vs. comparator* (recurrent or fatal VTE) Yes DVT Yes Major bleeding vs. comparator* ns ns Major or CRNM bleeding vs. comparator* PE Yes Yes ns ns Dosing BID BID then QD BID Head-to-head studies have not been conducted, therefore comparative safety and efficacy have not been established. *Comparator was LMWH or UFH followed by either a vitamin K antagonist (warfarin or acenocoumarol) in the rivaroxaban trials or warfarin in the other NOAC trials. BID, twice daily; CRNM, clinically relevant non-major; QD, once daily; LMWH, low molecular weight heparin; NOAC, novel oral anticoagulant; UFH, unfractionated heparin; VTE, venous thromboembolism 1. Agnelli G et al. N Engl J Med 2013;369: ; 2. The EINSTEIN Investigators. N Engl J Med 2010;363: ; 3. The EINSTEIN-PE Investigators. N Engl J Med 2012;366: ; 4. Schulman et al. N Engl J Med. 2009;361: ; 5. Schulman et al. Circulation;2014:129:
16 DOACs and VTE prolonged phase Non head-to-head comparisons APIXABAN 1 RIVAROXABAN 2 DABIGATRAN 3 Trial design: double-blind Yes Yes Yes Comparator Placebo Placebo Placebo Duration of treatment 12 months 6 or 12 months 6 months Dosing BID QD BID Dose(s) of NOAC studied 2.5 mg and 5 mg 20 mg 150 mg Superior efficacy (recurrent or fatal VTE) vs comparator Yes Yes Yes Major bleeding vs comparator ns ns ns Major or clinically-relevant non-major bleeding vs comparator ns Head-to-head studies have not been conducted, therefore comparative safety and efficacy have not been established BID, twice daily; NOAC, novel oral anticoagulant; ns, not significant; QD, once daily. 1.Agnelli et al. N Engl J Med 2013;368: The EINSTEIN Investigators. N Engl J Med. 2010;363: Schulman et al. N Engl J Med. 2013; 368:
17 Real life: FDA 2014: 134,414 patients Dabigatran and Warfarin for AF 2010 à 2012 Medicare 1 > patients RE-LY 2 4 > patients In the USA, the licensed doses for dabigatran etexilate are 150 mg BID and 75 mg BID for the prevention of stroke and systemic embolism in adult patients with nonvalvular AF. Numbers on bars denote hazard ratios vs warfarin; MI = myocardial infarction 1. Accessed on August 2014; 2. Connolly SJ et al. N Engl J Med 2009;361: ; 3. Connolly SJ et al. N Engl J Med. 2010;363:1875 6; 4. Pradaxa : EU SPC 2014
18 Real life: Quebec registry, 12,840 patients Dabigatran and Warfarin for AF INESSS 2013
19 In this combined analysis of real-world observational comparison studies with VKA, dabigatran was associated with: Lower risk of ischaemic stroke, major bleeding, intracranial bleeding and mortality Higher risk of GI bleeding Similar risk of myocardial infarction. Carmo J et al TH 2016
20 Dabigatran vs VKA for AF Ischemic Stroke
21 Dabigatran vs VKA for AF Major bleeding
22 Dabigatran vs VKA for AF Intracranial bleeding
23 Dabigatran vs VKA for AF Mortality
24 Dabigatran vs VKA for AF Gastrointestinal bleeding
25 Dabigatran vs VKA for AF Myocardial infarction
26 Real-world EVIdence on Stroke prevention In patients with atrial Fibrillation in the US Objective: To assess the real-world effectiveness and safety of newly-initiated rivaroxaban or apixaban compared to warfarin in NVAF patients 38,831 patients Rivaroxaban vs Warfarin 18, 591 patients Apixaban vs Warfarin Coleman CI et al, ESC 2016: P2576
27 Rivaroxaban vs Warfarin Rivaroxaban was associated with a significant* 47% reduction in ICH vs. warfarin 29% non-significant decrease in ischaemic stroke vs. warfarin Significant* 39% reduction in the combined endpoint of ICH and ischemic stroke vs. warfarin Rivaroxaban Warfarin HR (95% CI) Rate (%/year) Rate (%/year) rivaroxaban vs. warfarin HR (95% CI) rivaroxaban vs. warfarin ICH ( ) Ischemic stroke ( ) Combined ( ) *p<0.05 Coleman CI et al, ESC 2016: P2576 Favors rivaroxaban Favors warfarin
28 Apixaban vs Warfarin Apixaban was associated with a significant* 62% reduction in ICH vs. warfarin 13% non-significant increase in ischemic stroke vs. warfarin Non-significant 37% reduction in the combined endpoint of ICH and ischemic stroke vs. warfarin Apixaban Warfarin HR (95% CI) Rate (%/year) Rate (%/year) apixaban vs. warfarin HR (95% CI) apixaban vs. warfarin ICH ( ) Ischemic stroke ( ) Combined ( ) *p<0.05 Coleman CI et al, ESC 2016: P2576 Favors apixaban Favors warfarin
29 Lip G et al. Int J Clin Pract 2016; 70:
30 Lip G et al. Throm Haemost 2016
31 Using a large US insurance database, we identified privately insured and Medicare Advantage patients with nonvalvular atrial fibrillation who were users of apixaban, dabigatran, rivaroxaban, or warfarin between October 1, 2010, and June 30, We created 3 matched cohorts using 1:1 propensity score matching: Apixaban versus warfarin (n = ) Dabigatran versus warfarin (n = ) Rivaroxaban versus warfarin (n = ) Yao X et al. J Am Heart Assoc. 2016
32 CONCLUSIONS Apixaban was associated with lower risks of both stroke and major bleeding Dabigatran was associated with similar risk of stroke but lower risk of major bleeding Rivaroxaban was associated with similar risks of both stroke and major bleeding in comparison to warfarin
33 "Strategic" messages DOACs vs VKA vs UHF/LMWH The benefit / risk ratio is better for AF (efficacy + ICH) and for VTE (bleeding) CKD (clear < ml/min) and mechanic valves are the major limiting factors for DOACs For cancer related VTE, LMWH are superior to VKA and possibly to DOACs For HIV related VTE, dabigatran and VKA are the best choices For pregnancy, LMWH are superior to VKA and DOACs
34 REFERENCES
35 THROMBOSIS CANADA: «App»
36 References: "App"
37
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationControversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk
Controversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk Boyoung Joung, MD, PhD Professor, Division of Cardiology Director of Electrophysiology Laboratory Severance Cardiovascular
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationBlood Day for Primary Care
Blood Day for Primary Care including the Anticoagulation, use of novel oral anticoagulants in DVT/PE & atrial fibrillation Marc Carrier MD MSc. FRCPC Department of Internal Medicine, Division of Hematology,
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationNovel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015
Novel Oral An,coagulants: Prac,cal Aspects Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015 The New Oral An,coagulants (NOACs) The Non VKA Oral An,coagulants (NOACs)
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationEvidences for real-life use in fragile patients: Renal failure and cancer
Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationNOACs Scegliere in Contesti Particolari
Gianluca Botto, FESC, FEHRA U.O.s. Elettrofisiologia ASST-Lariana, Como NOACs Scegliere in Contesti Particolari Presenter Disclosure Information Research support: Boston Scientific, Medtronic; St. Jude
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationNew drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle
New drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle CONCLUSIONS 1. Arrival of new anticoagulants is a Good Thing. CONCLUSIONS 1. Arrival of new anticoagulants
More informationThe clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationIncidence and Impact of Antithrombotic-related Intracerebral Hemorrhage
Incidence and Impact of Antithrombotic-related Intracerebral Hemorrhage John J. Lewin III, PharmD, MBA, BCCCP, FASHP, FCCM, FNCS Division Director, Critical Care & Surgery Pharmacy Services, The Johns
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationΑντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη
Αντιπηκτική αγωγή 2017 Νέες μελέτες, πραγματικά δεδομένα και κλινική πράξη Σταύρος Β. Κωνσταντινίδης, MD, PhD, FESC Καθηγητής Καρδιολογίας Δημοκρίτειο Πανεπιστήμιο Θράκης skonst@med.duth.gr Medical Director
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationNew areas of development for the direct oral anticoagulants
New areas of development for the direct oral anticoagulants Varese March 2016 Disclosures for Harry R Büller Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationNovel Anticoagulants : Bleeding and Bridging
Novel Anticoagulants : Bleeding and Bridging Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA, FRCP, MA Professor, Thomas Jefferson Medical School Director Atrial Fibrillation Research and Education The
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More informationNOAC s across indications
Sektion CAMPUS INNENSTADT Med. Klinik und Poliklinik IV NOAC s across indications Ulrich Hoffmann, M.D. Division of Vascular Medicine University Hospital Munich, Germany Disclosure Speaker name: Ulrich
More informationTSHP 2014 Annual Seminar 1
Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationΕπιλέγοντας NOACs. Επηρεάζουν την απόφασή μας τα δεδομένα από την καθημερινή κλινική πρακτική;
2ο ΣΥΝΕΔΡΙΟ ΚΑΡΔΙΑΓΓΕΙΑΚΗΣ ΑΠΕΙΚΟΝΙΣΗΣ ΑΘΗΝΑ 2017 Επιλέγοντας NOACs. Επηρεάζουν την απόφασή μας τα δεδομένα από την καθημερινή κλινική πρακτική; Κωνσταντίνος Π. Λέτσας, MD, FEHRA Β Καρδιολογική Κλινική
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Anticoagulatns New Agents, Reversal and Bridging William
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationAF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China Case report 64-year-old Chinese man with history of hypertension,
More informationBoehringer-Ingelheim satellite symposium Ligue cardiologique belge 13/05/2017
Boehringer-Ingelheim satellite symposium Ligue cardiologique belge 13/05/2017 Dr André Peeters Service de Neurologie Cliniques Universitaires Saint-Luc / U.C.L. 1200 BRUXELLES Introduction 1. Aim NOACS
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationDisclosures. Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation
12:45 1:45 pm Practical Considerations for Anticoagulation for Prevention of Venous Thromboembolism and Stroke Due to Atrial Fibrillation SPEAKER Christian Ruff, MD, MPH Presenter Disclosure Information
More informationΧάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ»
Η ισορροπία ασφάλειας και αποτελεσματικότητας: Η συνέπεια στα αποτελέσματα των τυχαιοποιημένων κλινικών μελετών και των δεδομένων κλινικής πρακτικής της Απιξαμπάνης Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό
More informationDavid Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu At the conclusion of this program, the audience should
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION Edoxaban (Lixiana SERVIER Canada Inc.) Indication: Prevention of Stroke and Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More information